Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras - PubMed (original) (raw)
Review
Sex and the course of HIV infection in the pre- and highly active antiretroviral therapy eras
Maria Prins et al. AIDS. 2005.
Abstract
We reviewed the available literature on the potential effects of sex on the course of HIV infection and found that there is little evidence for sex differences in the rate of disease progression in the pre-highly active antiretroviral therapy (HAART) and HAART era. Compared to men, women appeared to have lower HIV RNA levels and higher CD4 cell counts shortly after infection with HIV, but studies were inconclusive regarding whether these differences diminish over time. Differences in viral load or CD4+ cell count might cause women to delay initiation of HAART. Nonetheless, we found no substantial sex difference in the benefit of antiretroviral therapy. The studies we reviewed failed to find any harmful effect of pregnancy on HIV disease progression. With the availability of effective antiretroviral agents, HIV-infected women have increasingly decided to have children. Conflicting results exist on the effect of HAART on regression of cervical intra-epithelial neoplasia (CIN). Unlike CIN, invasive cervical cancer has not been found to be much higher in HIV-infected women than in HIV-uninfected women. Although publication bias cannot be ruled out, published studies suggest higher rates of adverse events among HIV-infected women on therapy as compared to men. As more pharmacological agents are developed, it is especially important that potential sex differences in pharmacodynamics are assessed. The relationship between metabolic abnormalities, changes in body habitus, and endocrine perturbations has not been extensively studied. Whether sex differences are due to unalterable genetic factors or social and environmental conditions, it is imperative that all HIV-infected individuals have equal access to interventions that can slow disease progression.
Similar articles
- Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy.
Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR. Tai JH, et al. J Infect Dis. 2007 Oct 1;196(7):1044-52. doi: 10.1086/520814. Epub 2007 Aug 29. J Infect Dis. 2007. PMID: 17763327 - Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D. Aziz N, et al. BJOG. 2013 Nov;120(12):1534-47. doi: 10.1111/1471-0528.12226. Epub 2013 Aug 7. BJOG. 2013. PMID: 23924192 - Effect of antiretroviral therapy on pregnancy outcome in HIV-1 positive women.
Kowalska A, Niemiec T, El Midaoui A, Burkacka E. Kowalska A, et al. Med Wieku Rozwoj. 2003 Oct-Dec;7(4 Pt 1):459-68. Med Wieku Rozwoj. 2003. PMID: 15010556 Clinical Trial. - Thymic function in HIV-infection.
Kolte L. Kolte L. Dan Med J. 2013 Apr;60(4):B4622. Dan Med J. 2013. PMID: 23651726 Review. - Pre-eclampsia: the role of highly active antiretroviral therapy and immune markers.
Phoswa WN, Naicker T, Ramsuran V, Moodley J. Phoswa WN, et al. Inflamm Res. 2019 Jan;68(1):47-57. doi: 10.1007/s00011-018-1190-3. Epub 2018 Oct 1. Inflamm Res. 2019. PMID: 30276649 Review.
Cited by
- Prevalent pregnancy, biological sex, and virologic response to antiretroviral therapy.
Westreich D, Evans D, Firnhaber C, Majuba P, Maskew M. Westreich D, et al. J Acquir Immune Defic Syndr. 2012 Aug 15;60(5):489-94. doi: 10.1097/QAI.0b013e318256b310. J Acquir Immune Defic Syndr. 2012. PMID: 22487586 Free PMC article. - Factors associated with HIV viral load suppression on antiretroviral therapy in Vietnam.
Rangarajan S, Donn JC, Giang le T, Bui DD, Hung Nguyen H, Tou PB, Danh TT, Tran NB, Nguyen DA, Hoang Nguyen BT, Doan VT, Nguyen NQ, Pham VP, Dao DG, Chen M, Zeng Y, Tieu TT, Tran MH, Le TH, Hoang XC, West G. Rangarajan S, et al. J Virus Erad. 2016 Apr 1;2(2):94-101. doi: 10.1016/S2055-6640(20)30466-0. J Virus Erad. 2016. PMID: 27482442 Free PMC article. - CCR5 expression is reduced in lymph nodes of HIV type 1-infected women, compared with men, but does not mediate sex-based differences in viral loads.
Meditz AL, Folkvord JM, Lyle NH, Searls K, Lie YS, Coakley EP, McCarter M, Mawhinney S, Connick E. Meditz AL, et al. J Infect Dis. 2014 Mar;209(6):922-30. doi: 10.1093/infdis/jit575. Epub 2013 Oct 31. J Infect Dis. 2014. PMID: 24179109 Free PMC article. - Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks.
Squires KE, Young B, Santiago L, Dretler RH, Walmsley SL, Zhao HH, Pakes GE, Ross LL, Shaefer MS. Squires KE, et al. HIV AIDS (Auckl). 2017 Mar 3;9:51-61. doi: 10.2147/HIV.S108756. eCollection 2017. HIV AIDS (Auckl). 2017. PMID: 28424561 Free PMC article. - Gender inequities in quality of care among HIV-positive individuals initiating antiretroviral treatment in British Columbia, Canada (2000-2010).
Carter A, Min JE, Chau W, Lima VD, Kestler M, Pick N, Money D, Montaner JS, Hogg RS, Kaida A. Carter A, et al. PLoS One. 2014 Mar 18;9(3):e92334. doi: 10.1371/journal.pone.0092334. eCollection 2014. PLoS One. 2014. PMID: 24642949 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials